{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:59Z","timestamp":1782197279936,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pharmacogenetic (PGx) testing of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 is increasingly utilised to personalise psychopharmacological treatment, but clear criteria for patient selection are lacking. We developed and conducted a pilot evaluation of a clinical decision-making tool, the CYPRI (CYP Pharmacogenetic Risk Index), which uses routinely available clinical and pharmacological data to estimate the likelihood of a clinically relevant and actionable PGx testing result. A pilot observational study involving 34 patients was conducted at Psychiatric Hospital Bohnice in Prague, Czech Republic. A significant correlation was observed between the CYPRI score and the IMPACT score (ordinal logistic regression: t\u2009=\u20093.279,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0011; Kendall\u2019s \u03c4\u2009=\u20090.46,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0011). Discriminative ability was high, with an area under the curve (AUC) of 0.83 (95% CI: 0.69\u20130.97), based on ROC analysis performed using two outcome categories (0\u20132 vs. \u2265 2 points of IMPACT score). The optimal cut-off was 4. The CYPRI score offers a straightforward method to prioritise patients for PGx testing, potentially enhancing cost-effectiveness and clinical outcomes in psychiatric care.\n                  <\/jats:p>","DOI":"10.1038\/s41397-026-00414-4","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:47:34Z","timestamp":1777466854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYPRI: a clinical decision-making tool to select psychiatric patients for pharmacogenetic testing"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-3834","authenticated-orcid":false,"given":"Ivana","family":"Ta\u0161kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"\u0160af\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-8584","authenticated-orcid":false,"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"414_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.15252\/embr.201642951","volume":"17","author":"S Trautmann","year":"2016","unstructured":"Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17:1245\u20139.","journal-title":"EMBO Rep"},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137\u201350.","journal-title":"Lancet Psychiatry"},{"key":"414_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700\u201312.","journal-title":"Lancet"},{"key":"414_CR4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0140-6736(18)31612-X","volume":"392","author":"V Patel","year":"2018","unstructured":"Patel V, Saxena S, Lund C, Thornicroft G, Baingana F, Bolton P, et al. The Lancet Commission on global mental health and sustainable development. Lancet. 2018;392:1553\u201398.","journal-title":"Lancet"},{"key":"414_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","volume":"27","author":"OD Howes","year":"2022","unstructured":"Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27:58\u201372.","journal-title":"Mol Psychiatry"},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"414_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"414_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.psychres.2018.12.053","volume":"271","author":"HV Solomon","year":"2019","unstructured":"Solomon HV, Cates KW, Li KJ. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 2019;271:604\u201313.","journal-title":"Psychiatry Res"},{"key":"414_CR9","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1017\/S0033291723002817","volume":"53","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Maruf AA, Marques DF, Brown LC, M\u00fcller DJ. The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review. Psychol Med. 2023;53:7983\u201393.","journal-title":"Psychol Med"},{"key":"414_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/ph14050487","volume":"14","author":"M Hahn","year":"2021","unstructured":"Hahn M, Roll SC. The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug-drug interactions: Drug-gene, drug-gene-gene and drug-drug-gene interactions. Pharmaceuticals (Basel). 2021;14:487.","journal-title":"Pharmaceuticals (Basel)"},{"key":"414_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14218\/JERP.2023.00042","volume":"9","author":"A Eckert","year":"2024","unstructured":"Eckert A, Frantz A, Scherf-Clavel M, Weber H, Unterecker S, Reif A, et al. Divergent phenotypes, actionable genotypes, and phenoconversion in a German psychiatric inpatient population: Results from the FACT-PGx study. J Explor Res Pharmacol. 2024;9:79\u201385.","journal-title":"J Explor Res Pharmacol"},{"key":"414_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","volume":"328","author":"DW Oslin","year":"2022","unstructured":"Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME care randomized clinical trial. JAMA. 2022;328:151\u201361.","journal-title":"JAMA"},{"key":"414_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","volume":"241","author":"JD Rosenblat","year":"2018","unstructured":"Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord. 2018;241:484\u201391.","journal-title":"J Affect Disord"},{"key":"414_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pgs-2019-0157","volume":"21","author":"L Brown","year":"2020","unstructured":"Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21:559\u201369.","journal-title":"Pharmacogenomics"},{"key":"414_CR15","unstructured":"ClinPGx Database. Available from: https:\/\/ClinPGx.com."},{"key":"414_CR16","unstructured":"Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines [Internet]. Available from: https:\/\/cpicpgx.org\/guidelines\/."},{"key":"414_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","volume":"11","author":"H Abdullah-Koolmees","year":"2020","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol. 2020;11:595219.","journal-title":"Front Pharmacol"},{"key":"414_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/clpt.2010.279","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"414_CR19","unstructured":"Canadian Pharmacogenomics Network for Drug Safety (CPNDS) [Internet]. 2004. Available from: https:\/\/cpnds.ubc.ca\/."},{"key":"414_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.therap.2016.09.014","volume":"72","author":"N Picard","year":"2017","unstructured":"Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA, et al. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie. 2017;72:185\u201392.","journal-title":"Therapie"},{"key":"414_CR21","unstructured":"International Society of Psychiatric Genetics. Genetic testing and psychiatric disorders: A statement from the International Society of Psychiatric Genetics. Brentwood (TN): ISPG; 2019. Available from: https:\/\/ispg.net\/genetic-testing-statement\/."},{"key":"414_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mp.2012.42","volume":"18","author":"JC Stingl","year":"2013","unstructured":"Stingl JC, Brockm\u00f6ller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273\u201387.","journal-title":"Mol Psychiatry"},{"key":"414_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","volume":"6","author":"MM Jukic","year":"2019","unstructured":"Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6:418\u201326.","journal-title":"Lancet Psychiatry"},{"key":"414_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/pharmaceutics11090453","volume":"11","author":"S Vilches","year":"2019","unstructured":"Vilches S, Tuson M, Vieta E, \u00c1lvarez E, Espadaler J. Effectiveness of a pharmacogenetic tool at improving treatment efficacy in major depressive disorder: A meta-analysis of three clinical studies. Pharmaceutics. 2019;11:453.","journal-title":"Pharmaceutics"},{"key":"414_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cpt.2748","volume":"112","author":"LC Brown","year":"2022","unstructured":"Brown LC, Stanton JD, Bharthi K, Maruf AA, M\u00fcller DJ, Bousman CA. Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective, controlled clinical trials. Clin Pharmacol Ther. 2022;112:1303\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"414_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04756-2","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry. 2023;23:334.","journal-title":"BMC Psychiatry"},{"key":"414_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/pgs-2018-0142","volume":"20","author":"CA Bousman","year":"2019","unstructured":"Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20:37\u201347.","journal-title":"Pharmacogenomics"},{"key":"414_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105009","volume":"101","author":"M Skokou","year":"2024","unstructured":"Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine. 2024;101:105009.","journal-title":"EBioMedicine"},{"key":"414_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/a-1096-1171","volume":"53","author":"VAD B\u00e4ttig","year":"2020","unstructured":"B\u00e4ttig VAD, Roll SC, Hahn M. Pharmacogenetic testing in depressed patients and interdisciplinary exchange between a pharmacist and psychiatrists results in reduced hospitalization times. Pharmacopsychiatry. 2020;53:185\u201392.","journal-title":"Pharmacopsychiatry"},{"key":"414_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","volume":"78","author":"F Milosavljevic","year":"2021","unstructured":"Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pe\u0161ic V, Molden E, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: A systematic review and meta-analysis. JAMA Psychiatry. 2021;78:270\u201380.","journal-title":"JAMA Psychiatry"},{"key":"414_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s44220-024-00240-2","volume":"2","author":"N Saadullah Khani","year":"2024","unstructured":"Saadullah Khani N, Hudson G, Mills G, Ramesh S, Varney L, Cotic M, et al. A systematic review of pharmacogenetic testing to guide antipsychotic treatment. Nat Ment Health. 2024;2:616\u201326.","journal-title":"Nat Ment Health"},{"key":"414_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","volume":"21","author":"K Karamperis","year":"2021","unstructured":"Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533\u201341.","journal-title":"Pharmacogenomics J"},{"key":"414_CR33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/cpt.2754","volume":"112","author":"SA Morris","year":"2022","unstructured":"Morris SA, Alsaidi AT, Verbyla A, Cruz A, Macfarlane C, Bauer J, et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: A systematic review. Clin Pharmacol Ther. 2022;112:1318\u201328.","journal-title":"Clin Pharmacol Ther"},{"key":"414_CR34","doi-asserted-by":"crossref","unstructured":"Young C, MacDougall D An overview of pharmacogenomic testing for psychiatric disorders: CADTH horizon scan. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023.","DOI":"10.51731\/cjht.2023.664"},{"key":"414_CR35","unstructured":"PharmGKB. The Pharmacogenomics Knowledge Base (PharmGKB) [Internet]. Available from: https:\/\/www.pharmgkb.org\/."},{"key":"414_CR36","unstructured":"Indiana University School of Medicine. Flockhart Table\u2122 Drug Interactions. [Internet]. Available from: https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00414-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00414-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00414-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:29Z","timestamp":1782195149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00414-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00414-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7193611\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to the conception, execution, or publication of this study. The study did not receive financial support from any pharmaceutical company. GHC Genetics provided pharmacogenetic testing kits for a portion of the patient cohort included in the study; the company had no role in study design, data collection, analysis, interpretation, manuscript preparation, or the decision to submit the article. IT was invited by GHC Genetics to deliver a lecture on pharmacogenetics in psychiatry at a local congress commemorating 100 years of the Psychiatric hospital in Opa\u0159any (Czech Republic). This lecture had a regional focus and was unrelated to the present study. MH is a member of CPIC. NS has nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study received approval from the Ethical Committee of Psychiatric Hospital Bohnice, Prague (Approval No. PNBek7\/2024). All data were fully anonymised prior to analysis and were managed in accordance with ethical and institutional standards. Since the study involved a retrospective evaluation of anonymised clinical data, patient consent for the study was not required. Consent for the PGx testing was obtained from all patients and documented in their medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the Ethics Committee"}},{"value":"The data analysed in this study originate from original clinical observations and internal analyses conducted within the study\u2019s framework. All tables and figures included in the manuscript were created by the authors and have not been reproduced or modified from previously published works.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Origin and Visualisation Statement"}}],"article-number":"19"}}